views
Catheter Related Bloodstream Infection Market to Reach US$ 2.1 Billion by 2023
Market Overview:
Catheter-related bloodstream infections (CRBSIs) occur when bacteria or other
pathogens enter the bloodstream through a catheter. These infections can be
life-threatening and require immediate medical attention. The demand for
catheter-related bloodstream infection products is driven by the increasing
number of patients requiring catheters for medical procedures, particularly in
hospitals and other healthcare settings. These products help in preventing and
managing infections, improving patient outcomes, and reducing healthcare costs
associated with treating CRBSIs.
Market Key Trends:
One of the key trends in the catheter-related bloodstream infection market
is the growing adoption of antimicrobial catheters. Antimicrobial catheters are
designed to prevent the attachment and growth of bacteria, thereby reducing the
risk of bloodstream infections. These catheters are coated with antimicrobial
agents such as silver or chlorhexidine, which have broad-spectrum antimicrobial
activity. The use of antimicrobial catheters has shown promising results in
reducing the incidence of CRBSIs in various clinical settings. The increasing
awareness about the benefits of antimicrobial catheters among healthcare
professionals and the growing focus on infection prevention are driving the
demand for these products in the market.
Segment Analysis:
The catheter-related bloodstream infection market can be segmented based on
catheter type, infection type, end-user, and region. One of the dominating
sub-segments in this market is the central venous catheters segment. This is
primarily due to the widespread usage of central venous catheters in various
medical procedures and the higher incidence of bloodstream infections
associated with them. Central venous catheters are commonly used for critical
care patients, cancer patients, and patients requiring long-term intravenous
therapies. These catheters provide easy access to the bloodstream, but they
also pose a higher risk of infection compared to other catheter types. As a
result, efforts to prevent and treat catheter-related bloodstream infections
have primarily focused on central venous catheters.
Key Takeaways:
The Global
Catheter-Related Bloodstream Infection Market is expected to witness
high growth, exhibiting a CAGR of 5.1%
over the forecast period (2023-2031). This growth can be attributed to several
factors. Firstly, the increasing prevalence of chronic diseases that require
catheter usage, such as cancer, cardiovascular diseases, and renal diseases, is
driving the demand for catheters. Additionally, the rising geriatric
population, with an increased susceptibility to infections, further contributes
to the market growth.
In terms of regional analysis, North America is anticipated to be the
fastest-growing and dominating region in the catheter-related bloodstream
infection market. This can be attributed to several factors, including the
presence of advanced healthcare infrastructure, high healthcare expenditure,
and the overall awareness regarding infection control and prevention.
Furthermore, the high prevalence of chronic diseases and the growing adoption
of advanced catheters in this region are fueling market growth.
Key players operating in the catheter-related bloodstream infection market
include Citius Pharmaceuticals, CorMedix, Geistlich Pharma, TauroPharm GmbH,
Fresenius Medical Care, AstraZeneca Pharma India Ltd., Glenmark Pharmaceuticals
Ltd., Xellia Pharmaceuticals Ltd., and Pfizer. These companies are focusing on
developing innovative catheter technologies, investing in research and
development, and collaborating with healthcare institutions to increase their
market share and provide effective solutions for catheter-related bloodstream
infections.
Read More - https://www.marketwebjournal.com/catheter-related-blood-stream-infection-market-analysis/
Comments
0 comment